<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198558</url>
  </required_header>
  <id_info>
    <org_study_id>D7060C00001</org_study_id>
    <secondary_id>2019-002128-33</secondary_id>
    <nct_id>NCT04198558</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability and Pharmacokinetics of MEDI0618 in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, placebo-controlled study of the safety and tolerability of single doses
      of MEDI0618 in healthy volunteer subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomised, double-blind, placebo-controlled study of the safety, tolerability and
      pharmacokinetics of single ascending doses of MEDI0618 in healthy male and female volunteers.

      This study will include 9 planned cohorts; 8 cohorts will receive single ascending doses of
      MEDI0618 or placebo by intravenous administration, 1 cohort will receive MEDI0618 or placebo
      by subcutaneous administration.All subjects will undergo scheduled safety, tolerability,
      pharmacokinetic and immunogenicity assessments while in the clinical unit and as outpatients
      to the end of the follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2019</start_date>
  <completion_date type="Anticipated">June 25, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Serious Adverse Events</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Heart Rate in beats per minute</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Blood pressure in mm Hg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Weight</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Weight in kg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Height in meters Height and weight will be combined to report BMI in kg/m^2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Chemistry</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Measurement of Albumin, Protein, Aspartate transaminase, Alanine transaminase, Alkaline phosphatase, Bilirubin, Calcium, Creatine phosphokinase, C-reactive protein, Glucose, Blood urea nitrogen, Phosphate, Potassium, Sodium, Chloride and Bicarbonate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haematology</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Measurement of Haemoglobin, Haematocrit, Leukocyte count, Platelet count, Erythrocyte count, Reticulocyte count, Mean corpuscular haemoglobin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thyroid Function</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Measurement of Thyroid-stimulating hormone and free thyroxine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Function</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Measurement of Glomerular filtration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Measurement of Haemoglobin, Leukocytes, Glucose, Protein and Creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12-Lead Electrocardiogram</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Measurement of Heart rate; PR, QRS, RR, QT and QTc intervals from digital recordings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>General physical examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Peak concentration of MEDI0618 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (tmax)</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Time to maximum concentration of MEDI0618 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUC)</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Calculated area under the concentration versus time curve for MEDI0618</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Time required for the plasma concentration of MEDI0618 to decrease by 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioavailability</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>The fraction of MEDI0618 administered that is available to the systemic circulation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-drug antibody incidence and titres</measure>
    <time_frame>Up to 85 days</time_frame>
    <description>Anti-drug (MEDI0618) antibody incidence and titres</description>
  </other_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI0618 or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI0618</intervention_name>
    <description>MEDI0618 A novel human immunoglobulin antibody</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_label>Dose Level 6</arm_group_label>
    <arm_group_label>Dose Level 7</arm_group_label>
    <arm_group_label>Dose Level 8</arm_group_label>
    <arm_group_label>Dose Level 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_label>Dose Level 6</arm_group_label>
    <arm_group_label>Dose Level 7</arm_group_label>
    <arm_group_label>Dose Level 8</arm_group_label>
    <arm_group_label>Dose Level 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women of non-childbearing potential aged 18 to 55 years

          -  Normal 12-lead ECG at screening and on day of dosing

          -  Physical examinations with no significant findings at screening

          -  Be able to understand and comply with protocol requirements

        Exclusion Criteria:

          -  Participation in another clinical study with an investigational product (IP) within
             half-lives of the IP or 3 months, whichever is longer, prior to screening

          -  Requires treatment with another biological therapeutic agent

          -  Inability to comply with study-related requirements

          -  History of severe allergy or hypersensitivity reactions

          -  History of significant psychiatric disorder

          -  Presence of any clinically significant illness

          -  History of cancer

          -  Any clinically important abnormality physical examination, vital signs, ECG or
             laboratory test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tharani Chessell, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stanislav Ignatenko, Medical Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite Research Organisation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tharani Chessell, PhD</last_name>
    <phone>+44 203 749 6574</phone>
    <email>tharani.chessell@azneuro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 25, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Double-blind</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Safety and Tolerability Study</keyword>
  <keyword>Healthy Volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

